At a glance
ClinicalIndex Comparison RecordN/ACompleted· 75 enrolled
Drug / intervention
HX106 590mg +2 moredietary
Likely dose
HX106 590mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of HX106 on Improvement in Cognitive-Bio-Markers of Memory Function in Healthy Adults With Subjective Memory Complaints
In Brief
A clinical study evaluating HX106 590mg, HX106 1180mg, and 1 other intervention for Healthy Adults With Subjective Memory Complaints. Completed, enrolled 75 participants across 1 site.
Detailed Summary
The objectives of the current study are to evaluate the efficacy and safety of HX106 in healthy adults with subjective memory complaints for improving cognitive and neurobiolgoical markers of memory.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2012
Primary CompletionJan 2013
First PostedOct 2013
TodayJul 2026
First PostedOct 8, 2013
Enrollment StartMar 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.7 years ago
Interventions
HX106 590mgdietary
HX106 1180mgdietary
Placebodietary